Browse selected scientific articles published in journals across the fields of molecular genetics, metabolism, and neurology to facilitate your understanding of the spectrum, molecular and genetic basis, and management of Duchenne muscular dystrophy (DMD)
Please select a publication review of interest below:
This article, in the European Journal of Paediatric Neurology, summarizes the Delphi consensus study, which aims to establish best practices for the transition of young people with Duchenne muscular dystrophy (DMD) to adult care, and ensure continuity of treatment
This article in the Journal of Comparative Effectiveness Research summarizes the Cincinnati study, which investigated the effectiveness of 2 corticosteroid treatments in prolonging motor function in Duchenne muscular dystrophy (DMD)
Published in the Journal of Neuromuscular Diseases, this paper compares the effectiveness of 2 different corticosteroids in preserving limb function in non-ambulatory patients with Duchenne muscular dystrophy (DMD)
Published in the Journal of Comparative Effectiveness Research, this paper compares the effectiveness of corticosteroids by age and disease progression across patients from a range of Phase 2b and Phase 3 clinical trials
Published in the New Emirates Medical Journal, this case report discusses the challenges of treatment access and meeting Duchenne muscular dystrophy (DMD) care guidelines in the Middle East in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)
This paper, published in the Journal of Neuromuscular Diseases, explores the key similarities and differences between 2 corticosteroid treatments and their effectiveness when used in patients with Duchenne muscular dystrophy (DMD)
Published in the Journal of Neurology, this is an updated interim report from the ongoing Strategic Targeting of Registries and International Database of Excellence (STRIDE) international, multicenter registry of real-world ataluren use in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)
This research article, published in the Journal of Neuromuscular Diseases, provides a review of the impact of timing of clinical interventions in patients with Duchenne muscular dystrophy (DMD)
This research article, published in PLoS ONE, provides a summary of the prognostic indicators of disease progression in Duchenne muscular dystrophy (DMD)
In this video, recorded in 2022 for the Video Journal of Biomedicine, 2 authors of a research article present the background and findings from their study of a mutation-specific treatment for nonsense mutation Duchenne muscular dystrophy (nmDMD)
This research article, published in the Journal of Comparative Effectiveness Research, provides results from a retrospective real-world analysis of corticosteroid use in patients with Duchenne muscular dystrophy (DMD)
This research article, published in Future Neurology, describes the symptoms of nonsense mutation Duchenne muscular dystrophy (nmDMD), and the impact of the condition on caregivers, at different stages of the disease
This case study, published in Acta Myologica, details an ambulant 2-year-old patient with nonsense mutation Duchenne muscular dystrophy (nmDMD), who received early treatment with a mutation-specific therapy in an expanded-access program
This research article, published in the Journal of Comparative Effectiveness Research, provides results of meta-analyses comparing the efficacy of different corticosteroids in the management of nonsense mutation Duchenne muscular dystrophy (nmDMD)
This research article, published in the Journal of Comparative Effectiveness Research, provides results from a study investigating the efficacy of a mutation-specific therapy in delaying loss of ambulation (LoA) and respiratory function in patients with nonsense mutation DMD (nmDMD)
This research article, published in the Journal of Patient Reported Outcomes, describes the development of a conceptual model of the impact of nonsense mutation Duchenne muscular dystrophy (nmDMD) on caregivers, based on interviews with parents of patients with the condition
This article, published in PharmacoEconomics, provides results from an investigation to determine the cost of illness of Duchenne muscular dystrophy (DMD)
This research article, published in the Journal of Patient Reported Outcomes, describes the development of a conceptual model of the symptoms and impacts of nonsense mutation Duchenne muscular dystrophy (nmDMD), based on qualitative interviews with caregivers
This research article, published in Muscle and Nerve, describes investigations into a well-developed analytical procedure for evaluating longitudinal treatment effects using the North Star Ambulatory Assessment (NSAA) data for illustration
This research article, published in Drug Metabolism and Pharmacokinetics, evaluates the in vitro and in vivo stability of ataluren-O-1β-acyl glucuronide metabolite
This research article, published in Pharmacology Research & Perspectives, investigates the plasma pharmacokinetics, metabolite profiles and their quantitative exposures in humans following a single oral dose of deflazacort
This research article, published in Pharmacology Research & Perspectives, evaluates cytochrome P450 (CYP)- and transporter-mediated drug interaction potentials of 6β-hydroxy-21-desacetyl deflazacort (6β-OH-21-desDFZ)
This research article, published in Pharmacology Research and Perspectives, describes the in vitro metabolism and enzyme kinetics of ataluren and its interaction with CYP enzymes
This research letter, published in the JAMA Network Open, presents an analysis of 2 randomized, double-blind, placebo-controlled trials of a mutation-specific DMD gene therapy
This article, published in the Journal ofClinical Medicine, evaluates the developmental trajectory of working memory in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)
This research article, published in the Journal ofComparative Effectiveness Research, examines the totality of efficacy evidence for a mutation-specific therapy in patients with nmDMD by meta-analysis
This research article, published in the Journal ofComparative Effectiveness Research, outlines the safety and effectiveness of a mutation-specific Duchenne muscular dystrophy (DMD) therapy in 2 propensity score-matched DMD patient populations
This clinical research article, published in the Muscle & Nerve Journal, compares disease progression among boys enrolled in the placebo arms of 2 DMD clinical trials receiving deflazacort or prednisone/prednisolone
This research article, published in the Journal ofComparative Effectiveness Research, outlines the initial demographics and baseline characteristics of patients enrolled in Strategic Targeting of Registries and International Database of Excellence (STRIDE), an observational registry of nmDMD patients receiving a mutation-specific DMD therapy
This research article, published in the Muscle & Nerve Journal, details a post hoc analysis of the placebo arm of the Ataluren Confirmatory Trial (ACT) Duchenne muscular dystrophy (DMD) study
Learn more about our phase I–III clinical trials, patient registries and natural history studies in DMD.
PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.
For medical information, product complaints, or to report an adverse event, please call 1-866-562-4620 or email at usmedinfo@ptcbio.com. You may also report adverse events directly to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
MED-ALL-DFZ-2500002 | March 2025
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC Therapeutics at pharmacovigilance@ptcbio.com.
Registration conditions differ internationally; always consult local prescribing information and/or Summary of Product Characteristics before prescribing any products.
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.
